Result of AGM

RNS

June 24th 2016

Horizon Discovery Group plc

Result of AGM

Cambridge, UK, 24 June 2016: Horizon Discovery Group plc (LSE: HZD) ("Horizon or "the Company"), the world-leader in the application of gene editing technologies, announces that at its Annual General Meeting held today at 10am at the Company's offices, Building 8100 Cambridge Research Park, Waterbeach, Cambridge, CB25 9TL, all resolutions were duly passed.

- ENDS -

For further information from Horizon Discovery Group plc, please contact:

Horizon Discovery Group plc

Darrin Disley, Chief Executive Officer

Richard Vellacott, Chief Financial Officer

Chris Claxton, VP Investor Relations & Corporate Communication

Tel: +44 (0)1223 655 580

Numis Securities Limited (Joint Broker and NOMAD)

Michael Meade / Freddie Barnfield

Tel: +44 (0) 207 260 1000

RBC Capital Markets (Joint Broker)

Paul Tomasic / Marcus Jackson

Tel: +44 (0) 20 7653 4000

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott / Amber Fennell / Sue Stuart / Matthew Neal

Tel: +44 (0) 20 3709 5701

Email: [email protected]

About Horizon Discovery Group plc

Horizon Discovery Group plc (LSE: HZD) ("Horizon"), is a world-leading gene editing company that designs and engineers genetically-modified cells and then applies them in research and clinical applications that advance human health. Horizon's core capabilities are built around its proprietary translational genomics platform, a highly precise and flexible suite of gene editing tools (rAAV, ZFN and CRISPR) able to alter almost any gene sequence in human or mammalian cell-lines. Horizon offers over 23,000 catalogue products and related research services, almost all of which are based on the generation and application of cell and in vivo models that accurately recapitulate the disease-causing genetic anomalies found in diseases like cancer. Horizon's commercial offering has been adopted by c1,400 unique research organisations in over 50 countries as well as in the Company's own R&D pipeline to support a greater understanding of the genetic drivers of disease and the development of molecular, cell and gene therapies that can be prescribed on a personalised basis. Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange's AIM market under the ticker "HZD".